van der Heijde D, Deodhar A, Baraliakos X, et al. Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials. Ann Rheum Dis 2023;82:515-26. doi: 10.1136/ard-2022-223595
Although the results were presented correctly, the summary in the discussion needs to be corrected:
‘Most fungal infections with bimekizumab were mild to moderate, and none were systemic or led to treatment discontinuation.’
Correct sentence:
‘Most cases of fungal infections with bimekizumab were mild to moderate, with only 2 leading to discontinuation, and no systemic fungal infections were reported.’